Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 2
1998 4
1999 2
2000 1
2001 3
2002 9
2003 4
2004 6
2005 6
2006 3
2007 1
2008 5
2009 4
2010 7
2011 11
2012 10
2013 17
2014 21
2015 28
2016 35
2017 45
2018 59
2019 53
2020 49
2021 49
2022 45
2023 51
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

490 results

Results by year

Filters applied: . Clear all
Page 1
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Lancaster LH, et al. Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29212837 Free PMC article. Review.
Long-term extension trials, registries and real-world studies have also shown similar treatment effects with pirfenidone. However, for patients with IPF to obtain the maximum benefits of pirfenidone treatment, the potential adverse events (AEs) associa …
Long-term extension trials, registries and real-world studies have also shown similar treatment effects with pirfenidone. Howe …
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. King TE Jr, et al. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836312 Free article. Clinical Trial.
We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo fo …
We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we …
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Noble PW, et al. Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13. Lancet. 2011. PMID: 21571362 Clinical Trial.
In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo. ...FINDINGS: In study 004, 174 of 435 patients we …
In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in stud …
Pirfenidone in idiopathic pulmonary fibrosis.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8. Eur Respir J. 2010. PMID: 19996196 Free article. Clinical Trial.
Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients. Pirfenidone was relatively well tolerated in patients with IPF. Treatment with pirfenidone
Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mi …
Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Ghazipura M, Mammen MJ, Bissell BD, Macrea M, Herman DD, Hon SM, Kheir F, Khor YH, Knight SL, Raghu G, Wilson KC, Hossain T. Ghazipura M, et al. Ann Am Thorac Soc. 2022 Jun;19(6):1030-1039. doi: 10.1513/AnnalsATS.202103-342OC. Ann Am Thorac Soc. 2022. PMID: 35499847
Objective: To conduct a systematic review to evaluate existing ILD literature to determine whether patients with progressive pulmonary fibrosis (PPF) should be treated with the antifibrotic pirfenidone. Data Sources: A literature search was conducted across MEDLINE, EMBASE …
Objective: To conduct a systematic review to evaluate existing ILD literature to determine whether patients with progressive pulmonary fibro …
Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
Kishaba T. Kishaba T. Medicina (Kaunas). 2019 Mar 16;55(3):70. doi: 10.3390/medicina55030070. Medicina (Kaunas). 2019. PMID: 30884853 Free PMC article. Review.
The International Working Group project proposed new criteria for defining AE of IPF in 2016, which divides it into triggered and idiopathic AE. ...In addition, two antifibrotic agents have become available. We should focus on both the management and prevention of …
The International Working Group project proposed new criteria for defining AE of IPF in 2016, which divides it into triggered and idi …
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Maher TM, et al. Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29. Lancet Respir Med. 2020. PMID: 31578169 Free article. Clinical Trial.
Treatment-emergent adverse events were reported in 120 (94%) of 127 patients in the pirfenidone group and 101 (81%) of 124 patients in the placebo group. Serious treatment-emergent adverse events were reported in 18 (14%) patients in the pirfenidone gr …
Treatment-emergent adverse events were reported in 120 (94%) of 127 patients in the pirfenidone group and 101 (81%) of 124 pat …
Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial.
West A, Chaudhuri N, Barczyk A, Wilsher ML, Hopkins P, Glaspole I, Corte TJ, Šterclová M, Veale A, Jassem E, Wijsenbeek MS, Grainge C, Piotrowski W, Raghu G, Shaffer ML, Nair D, Freeman L, Otto K, Montgomery AB. West A, et al. Thorax. 2023 Sep;78(9):882-889. doi: 10.1136/thorax-2022-219391. Epub 2023 Mar 22. Thorax. 2023. PMID: 36948586 Free article. Clinical Trial.
INTRODUCTION: Oral pirfenidone reduces lung function decline and mortality in patients with idiopathic pulmonary fibrosis (IPF). Systemic exposure can have significant side effects, including nausea, rash, photosensitivity, weight loss and fatigue. ...
INTRODUCTION: Oral pirfenidone reduces lung function decline and mortality in patients with idiopathic pulmonary fibrosis (IPF). Syst …
Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model.
Tanner L, Single AB, Bhongir RKV, Heusel M, Mohanty T, Karlsson CAQ, Pan L, Clausson CM, Bergwik J, Wang K, Andersson CK, Oommen RM, Erjefält JS, Malmström J, Wallner O, Boldogh I, Helleday T, Kalderén C, Egesten A. Tanner L, et al. Nat Commun. 2023 Feb 6;14(1):643. doi: 10.1038/s41467-023-36314-5. Nat Commun. 2023. PMID: 36746968 Free PMC article.
Interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF) are caused by persistent micro-injuries to alveolar epithelial tissues accompanied by aberrant repair processes. IPF is currently treated with pirfenidone and nintedanib, compounds which slow the rate o …
Interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF) are caused by persistent micro-injuries to alveolar epithelial tissue …
Pirfenidone-induced phototoxic reaction.
Morgado-Carrasco D, Massana J, Piquero-Casals J. Morgado-Carrasco D, et al. Int J Dermatol. 2021 May;60(5):e202-e203. doi: 10.1111/ijd.15361. Epub 2020 Dec 8. Int J Dermatol. 2021. PMID: 33615459 No abstract available.
490 results